Economic evaluation of vaccination against COVID‐19: A systematic review
Abstract Background and Aims Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic rev...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1871 |
| _version_ | 1797221157314756608 |
|---|---|
| author | Dolatshahi Zeinab Nargesi Shahin Mezginejad Fateme Bagheri Faradonbeh Saeed |
| author_facet | Dolatshahi Zeinab Nargesi Shahin Mezginejad Fateme Bagheri Faradonbeh Saeed |
| author_sort | Dolatshahi Zeinab |
| collection | DOAJ |
| description | Abstract Background and Aims Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid‐19 to all health policymakers worldwide. Methods Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as “Vaccination,” “Covid‐19,” “Cost‐benefit,” “Cost‐utility,” “Cost‐effectiveness,” “Economic Assessment,” and “Economic evaluation.” Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review. Results All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost‐effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost‐benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered. Conclusion The COVID‐19 primary vaccination programs in regional outbreaks, from a long‐term perspective, will demonstrate substantial cost‐effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX‐19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world. |
| first_indexed | 2024-03-07T19:01:32Z |
| format | Article |
| id | doaj.art-9287b5366e984729b86b4bf10e42da02 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-04-24T13:00:58Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-9287b5366e984729b86b4bf10e42da022024-04-05T11:41:32ZengWileyHealth Science Reports2398-88352024-02-0172n/an/a10.1002/hsr2.1871Economic evaluation of vaccination against COVID‐19: A systematic reviewDolatshahi Zeinab0Nargesi Shahin1Mezginejad Fateme2Bagheri Faradonbeh Saeed3Department of Health Policy, School of Health Management and Information Sciences Iran University of Medical Sciences Tehran IranDepartment of Health Management and Economics, Faculty of Health Ilam University of Medical Sciences Ilam IranDepartment of Hematology, School of Allied Medicine, Cellular and Molecular Research Center Birjand University of Medical Sciences Birjan IranDepartment of Health Services Management, School of Health Ahvaz Jundishapur University of Medical Science Ahvaz IranAbstract Background and Aims Coronavirus has burdened considerable expenditures on the different health systems. Vaccination programs, the critical solution against pandemic diseases, are known as safe and effective interventions to prevent and control epidemics. We aimed to perform a systematic review to provide economic evidence of the value of different types of vaccines available to combat the Covid‐19 to all health policymakers worldwide. Methods Electronic searches conducted on Medline/PubMed, Cochrane Library, Web of Science, Scopus, Embase, and other economic evaluation databases. Related and published articles searched up to March 2022 by using keywords such as “Vaccination,” “Covid‐19,” “Cost‐benefit,” “Cost‐utility,” “Cost‐effectiveness,” “Economic Assessment,” and “Economic evaluation.” Followed by choosing the most suitable articles according to inclusion and exclusion criteria, data captured and the results extracted. The quality assessment of the articles performed by the checklist of CHEERS 2022. Finally, 13 articles included in the review. Results All messenger RNA vaccines were dominant with approximately 70% coverage against no vaccination in the primary vaccination program except in one study that looked at booster effects. From a payer's perspective, a dollar invested in a vaccine would be less profitable than from a societal perspective. Therefore, primary mass vaccination can be considered a cost‐effective intervention in primary vaccination to save more lives and produce more positive externalities. However, the cost‐benefit ratio for all vaccines increases when statistical lifetime value and global economic and educational disadvantages are considered. Conclusion The COVID‐19 primary vaccination programs in regional outbreaks, from a long‐term perspective, will demonstrate substantial cost‐effectiveness. It is suggested that due to the positive externalities of vaccination, primary mass vaccination, with the help of COVAX‐19TM, could be considered a reliable way to combat viral epidemics compared to the loss of individual lives and economic and educational disturbances around the world.https://doi.org/10.1002/hsr2.1871cost‐benefit analysiscost‐effectiveness analysiscost‐utility analysisCOVID‐19vaccine |
| spellingShingle | Dolatshahi Zeinab Nargesi Shahin Mezginejad Fateme Bagheri Faradonbeh Saeed Economic evaluation of vaccination against COVID‐19: A systematic review Health Science Reports cost‐benefit analysis cost‐effectiveness analysis cost‐utility analysis COVID‐19 vaccine |
| title | Economic evaluation of vaccination against COVID‐19: A systematic review |
| title_full | Economic evaluation of vaccination against COVID‐19: A systematic review |
| title_fullStr | Economic evaluation of vaccination against COVID‐19: A systematic review |
| title_full_unstemmed | Economic evaluation of vaccination against COVID‐19: A systematic review |
| title_short | Economic evaluation of vaccination against COVID‐19: A systematic review |
| title_sort | economic evaluation of vaccination against covid 19 a systematic review |
| topic | cost‐benefit analysis cost‐effectiveness analysis cost‐utility analysis COVID‐19 vaccine |
| url | https://doi.org/10.1002/hsr2.1871 |
| work_keys_str_mv | AT dolatshahizeinab economicevaluationofvaccinationagainstcovid19asystematicreview AT nargesishahin economicevaluationofvaccinationagainstcovid19asystematicreview AT mezginejadfateme economicevaluationofvaccinationagainstcovid19asystematicreview AT bagherifaradonbehsaeed economicevaluationofvaccinationagainstcovid19asystematicreview |